Investing.comDoubao · 实盘不做把握 8/10不做原因:风险收益比不佳
北京时间·🕒 发布 00:12:48·⟳ 抓取 00:13:07 +19s·⚡ 决策 10-13 00:15:01 +1m54s·14.9 天前
Regeneron公布FOP药物Pasatru III期OPTIMA 84周延展期数据：疗效持续维持，但属已获批药物的确认性数据
Pasatru此前已凭56周数据获FDA批准，84周数据只是学术会议上的耐久性确认，不改变获批状态、标签范围、指引或销售预期；FOP为全球仅约数千患者的超罕见适应症，对应收入相对Regeneron约787亿美元市值（Dupixent/Eylea为核心）微不足道，属超大盘股的软催化，无正期望edge。
📄 原文Investing.com↗ 原文
Regeneron reports sustained efficacy for FOP treatment Pasatru
S&P 500 little changed, Dow and Nasdaq mixed ahead of bank earnings, CPI this week TARRYTOWN, N.Y. - Regeneron Pharmace…
不做 Regeneron Pharmaceuticals（REGN.US）
软催化：Pasatru已获FDA批准，84周延展数据仅为学术会议确认性更新，无审批/标签/指引增量；FOP超罕见病收入对约787亿美元市值无实质弹性，盘中+2.36%无放量支撑，无edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Regeneron公布的是已获批超罕见病药物Pasatru的84周确认性数据，方向正面但无收入或监管状态增量；对约787亿美元市值的REGN不构成可交易催化，回避。
🔎 新鲜度:最早出现 2026-10-12 · 扩散 low · price-in 风险 medium ↗
关键理由
- 84周数据方向正面（零新发病灶、发作持续受抑、安全性可控），对EMA审评和长期用药依从性构成温和支持
主要风险
- 10mg/kg组皮肤软组织感染率78%高于安慰剂33%，虽均缓解且无停药，但长期安全性仍可能影响高剂量使用
- 数据为63人小样本延展的亚组比较，学术会议数据不构成新的商业化里程碑
反向证据
- 做多前查反向 · 来源 web · 影响 invalidates
FOP为超罕见病（全球患者仅约数千人），FOP单项收入潜力相对REGN约787亿美元市值占比不足1%，且本次无新适应症或标签事件
检索:Pasatru FOP peak sales materiality Regeneron garetosmab revenue estimate 原文 ↗
先例如何影响了这次决策
对本次决策的影响:不影响结论：无论先例涨跌，相对约787亿美元市值的增量过小，直接AVOID
方向:未做先例统计：已获批超罕见病药物学术会议确认性数据对超大盘药企股价无可交易量级，先例不会改变materiality结论
涨幅量级:无足够高相似先例校准幅度，且不需要——事件本身无财务增量
形态:不适用
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 13 ms
{"result": "search_processed_events:agent query=`regeneron garetosmab fibrodysplasia ossificans progressiva phase 3 results asbmr | regeneron pasatru fop 84-week optima extension data | regn pasatru fda approval fop flare-up hete`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - stock_quote 成功 stock_tools HTTP · 190 ms
{
原文全文
展开原文 · 1,970 字
S&P 500 little changed, Dow and Nasdaq mixed ahead of bank earnings, CPI this week
TARRYTOWN, N.Y. - Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced results from an 84-week extension of its Phase 3 OPTIMA trial evaluating Pasatru in adults with fibrodysplasia ossificans progressiva, according to a press release statement.
The data, presented today at the American Society for Bone and Mineral Research Annual Meeting, showed no new heterotopic ossification lesions at week 84 for Pasatru compared to nine new lesions for placebo as assessed by computed tomography scan. One lesion previously detected at week 56 for the 3 mg/kg dose was no longer detectable at week 84.
New clinician-assessed flare-ups numbered one for Pasatru 10 mg/kg, 14 for Pasatru 3 mg/kg, and 17 for placebo from week 56 to week 84.
The trial enrolled 63 participants aged 18 years and older with FOP, randomized to receive Pasatru 10 mg/kg, Pasatru 3 mg/kg, or placebo once every four weeks for 56 weeks. Following this period, 58 participants completed the double-blind extension phase to at least 84 weeks.
At 84 weeks, the most common treatment-emergent adverse events were acne in participants treated with Pasatru 10 mg/kg and epistaxis in participants treated with Pasatru 3 mg/kg. Skin and soft tissue infections occurred in 33% on placebo, 53% on Pasatru 3 mg/kg, and 78% on Pasatru 10 mg/kg. All infections resolved with management, and no patients discontinued treatment as a result. No deaths were reported in the trial.
Pasatru received FDA approval based on 56-week data to reduce formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP. A regulatory submission is under review by the European Medicines Agency.
Regeneron plans to begin a Phase 3 trial of Pasatru in adolescents and children with FOP later this year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
TARRYTOWN, N.Y. - Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced results from an 84-week extension of its Phase 3 OPTIMA trial evaluating Pasatru in adults with fibrodysplasia ossificans progressiva, according to a press release statement.
The data, presented today at the American Society for Bone and Mineral Research Annual Meeting, showed no new heterotopic ossification lesions at week 84 for Pasatru compared to nine new lesions for placebo as assessed by computed tomography scan. One lesion previously detected at week 56 for the 3 mg/kg dose was no longer detectable at week 84.
New clinician-assessed flare-ups numbered one for Pasatru 10 mg/kg, 14 for Pasatru 3 mg/kg, and 17 for placebo from week 56 to week 84.
The trial enrolled 63 participants aged 18 years and older with FOP, randomized to receive Pasatru 10 mg/kg, Pasatru 3 mg/kg, or placebo once every four weeks for 56 weeks. Following this period, 58 participants completed the double-blind extension phase to at least 84 weeks.
At 84 weeks, the most common treatment-emergent adverse events were acne in participants treated with Pasatru 10 mg/kg and epistaxis in participants treated with Pasatru 3 mg/kg. Skin and soft tissue infections occurred in 33% on placebo, 53% on Pasatru 3 mg/kg, and 78% on Pasatru 10 mg/kg. All infections resolved with management, and no patients discontinued treatment as a result. No deaths were reported in the trial.
Pasatru received FDA approval based on 56-week data to reduce formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP. A regulatory submission is under review by the European Medicines Agency.
Regeneron plans to begin a Phase 3 trial of Pasatru in adolescents and children with FOP later this year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
1797d5c9f4· 2026-10-13 00:15 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前